Seminar Dr. Tayyaba Hasan
Speaker: Tayyaba Hasan is a Professor of Dermatology at Harvard Medical School (HMS), Wellman Center for Photomedicine, Massachusetts General Hospital (MGH) and Professor of Health Sciences & Technology at Harvard-MIT. Her research is in photobiology and photodynamic therapy with over 200 publications and several patents. Dr. Hasan’s research is funded primarily by the NIH/NCI in the form of PO1, RO1s and R33s. She is the Program Director for a National Cancer Institute multi-site Program Project, and holds several other grants from the DoD and industry. Dr. Hasan is an inventor of the FDA approved photodynamic treatment of Age-Related Macular Degeneration. In recognition for this translational work and other discoveries, Dr. Hasan was the recipient for the Bench to Bedside Pioneer Award from the National Institutes of Health. She has had a long term involvement in helping the career development of junior scientists and was the first Director of the Office forResearch Career Development at MGH until 2011. Her commitment to teaching and training has earned her the William Silen Lifetime Achievement in Mentoring Award from HMS. She has been invited to several institutions to discuss mentoring and career development and was selected as the keynote speaker at the Annual Meeting of Massachusetts General Postdoctoral Association (MGPA) who named the Annual Lecture in her honor. She is the recipient for the Tenth Anniversary Mentor Award from the National Postdoctoral Association (NPA). Dr. Hasan has had a long term interest in international research, education and mentoring. As part of this effort, she has collaborative grants with Israel, Pakistan, China and Korea. She also trains international students in the Wellman-MIT summer bio-optics program.
Location: Biodesign Auditorium
Web Cast: View Webcast
Title: Photodynamic Therapy: A slice of biophotonics bridging science, technology and medicine
Abstract: Absorption of light by endogenous or exogenous cells and/or tissue-associated chromophores creates photophysical processes that are captured for diagnostic uses and for surgical guidance, in addition to treatment purposes. Such a process also provides a tool for the mechanistic understanding of disease pathology and tissue responses to various therapeutic interventions. Photodynamic therapy (PDT), a modality approved by regulatory agencies worldwide, for clinical use in cancer and non-cancer diseases, is a photochemistry based process resulting from the light activation of exogenous chemicals localized at anatomical sites of disease. The active molecular species produced by the molecular excited state destroys biological targets in the vicinity. A small fraction of the excited state de-energizes via fluorescence thus providing an opportunity to use the same molecule for detection/diagnostics and therapy. As with any therapy, PDT elicits specific molecular responses that can be
exploited to enrich our arsenal of treatments. The presentation will discuss the current state of PDT as a theranostic modality and on future directions.
Thank you and if you have questions please contact Christina Cates! And don’t forget, coffee will be served!
Christina Cates, Center for the Convergence of Physical Science and Cancer Biology
Arizona State University | P.O. Box 871504 | Tempe, AZ 85287
480.965.0342 | Fax: 480.965.6362